PARIS (Reuters) – Clinical diagnostics company Novacyt – one of many healthcare companies whose shares have surged during the pandemic – announced on Thursday a new product to allow people to differentiate the COVID-19 virus from common winter diseases.
Novacyt said its new ‘Winterplex’ test panel includes two gene targets specific to COVID-19, as well as gene targets for influenza A&B and respiratory syncytial virus (RSV).
“We believe Winterplex
is one of the world’s first approved respiratory test panels that can differentiate between COVID-19 and other common respiratory diseases,” Novacyt CEO Graham Mullis said.
(Reporting by Sudip Kar-Gupta; editing by Jason Neely)
